Inhaled Insulin Returns To The U.S. Market With Afrezza Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi announced the launch of the inhaled insulin in the U.S. Feb. 3, priced at a wholesale acquisition cost that is higher than rival injectable mealtime insulins.